We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Fluorescence Probe Paired with Engineered Enzymes Lights Up Tumors for Easier Surgical Removal

By HospiMedica International staff writers
Posted on 06 Mar 2026

Successful cancer surgery relies on a surgeon’s ability to remove tumors while preserving as much healthy tissue as possible. More...

To assist with this, surgeons often use fluorescent dyes that cause cancer cells to glow under special imaging systems. However, current dyes are not perfectly selective and can sometimes illuminate healthy tissue, making it difficult to distinguish tumors clearly during surgery. Researchers have now developed a new fluorescence system designed to highlight tumors with far greater precision.

Researchers at the University of Tokyo (Tokyo, Japan) have created what they describe as a bioorthogonal fluorescence probe paired with a specially engineered reporter enzyme that activates the probe only at targeted tumor sites. Unlike traditional probes that may be triggered by natural enzymes found throughout the body, this new probe remains inactive unless it encounters its matching engineered enzyme. This design significantly reduces unwanted background fluorescence.

To test the system, researchers delivered the engineered enzyme to tumor sites in mice with peritoneal cancer. Once the enzyme accumulated in the tumor tissue, the fluorescent probe was administered. The probe activated only when it encountered the engineered enzyme, causing the tumors to light up clearly. The study, published in American Chemical Society, shows that the approach allowed scientists to detect millimeter-sized tumor lesions with very low background fluorescence. The high contrast made tumors easier to distinguish from surrounding healthy tissue, potentially improving surgical precision.

Researchers believe this technology could eventually help surgeons identify and remove tumors more accurately during cancer surgery. The enzyme–probe system may also be adaptable to other cancer types by modifying the tumor-targeting component, such as using antibodies that recognize specific tumor markers. In addition to imaging, the approach could potentially be used for targeted drug delivery, where therapeutic agents are activated only at tumor sites. However, the current results are based on mouse studies, and further research is required before the technology can be tested in humans.

“Older probes often light up healthy tissue by mistake, creating background noise, but our highly selective, or bioorthogonal, dye probe is designed to stay completely off unless it meets its matching engineered enzyme,” said Associate Professor Ryosuke Kojima. “In the near term, this system could become a powerful research tool, and in the longer term, it may help surgeons remove tumors more completely by clearly highlighting cancer cells.’

Related Links:
University of Tokyo


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.